Zenas Biopharma Inc
NASDAQ:ZBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Z
|
Zenas Biopharma Inc
NASDAQ:ZBIO
|
US |
|
Borealis Mining Company Ltd
XTSX:BOGO
|
CA |
|
TIE Kinetix NV
AEX:TIE
|
NL |
|
Kaleido Biosciences Inc
OTC:KLDO
|
US |
|
Zimplats Holdings Ltd
ASX:ZIM
|
GG |
|
LINKBANCORP Inc
NASDAQ:LNKB
|
US |
|
Fameglow Holdings Ltd
HKEX:8603
|
HK |
|
T
|
tripla Co Ltd
TSE:5136
|
JP |
|
DG Innovate PLC
LSE:DGI
|
UK |
|
J
|
Jiangxi Copper Co Ltd
XBER:JIX
|
CN |
Zenas Biopharma Inc
Zenas Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Waltham, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2024-09-13. Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is focused on the development and commercialization of immunology-based therapies for patients in need. Its lead immunology and inflammation (I&I) product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The company is developing obexelimab as a potential I&I franchise for patients in several autoimmune diseases. Its pipeline also includes two global programs, ZB002 (an anti-TNFα monoclonal antibody) and ZB004 (a CTLA-4-Ig fusion), and two regional programs, ZB001 (also known as VRDN-001, an IGF-1R monoclonal antibody), and related programs, and ZB005 (also known as DNTH103, an anti-active C1s monoclonal antibody), for which the Company hold the development and commercialization rights in greater China.
Zenas Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Waltham, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2024-09-13. Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is focused on the development and commercialization of immunology-based therapies for patients in need. Its lead immunology and inflammation (I&I) product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The company is developing obexelimab as a potential I&I franchise for patients in several autoimmune diseases. Its pipeline also includes two global programs, ZB002 (an anti-TNFα monoclonal antibody) and ZB004 (a CTLA-4-Ig fusion), and two regional programs, ZB001 (also known as VRDN-001, an IGF-1R monoclonal antibody), and related programs, and ZB005 (also known as DNTH103, an anti-active C1s monoclonal antibody), for which the Company hold the development and commercialization rights in greater China.
